These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16091248)

  • 41. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.
    Fisac C; Virgili N; Ferrer E; Barbera MJ; Fumero E; Vilarasau C; Podzamczer D
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5186-92. PubMed ID: 14602748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.
    Xu A; Yin S; Wong L; Chan KW; Lam KS
    Endocrinology; 2004 Feb; 145(2):487-94. PubMed ID: 14592951
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.
    Dubé MP; Stein JH; Aberg JA; Fichtenbaum CJ; Gerber JG; Tashima KT; Henry WK; Currier JS; Sprecher D; Glesby MJ; ;
    Clin Infect Dis; 2003 Sep; 37(5):613-27. PubMed ID: 12942391
    [No Abstract]   [Full Text] [Related]  

  • 44. Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study.
    Petit JM; Duong M; Florentin E; Duvillard L; Chavanet P; Brun JM; Portier H; Gambert P; Verges B
    J Lipid Res; 2003 Sep; 44(9):1692-7. PubMed ID: 12869587
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV protease inhibitors acutely impair glucose-stimulated insulin release.
    Koster JC; Remedi MS; Qiu H; Nichols CG; Hruz PW
    Diabetes; 2003 Jul; 52(7):1695-1700. PubMed ID: 12829635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alterations in lipid kinetics in men with HIV-dyslipidemia.
    Reeds DN; Mittendorfer B; Patterson BW; Powderly WG; Yarasheski KE; Klein S
    Am J Physiol Endocrinol Metab; 2003 Sep; 285(3):E490-7. PubMed ID: 12746213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipid evaluation in HIV-1-positive patients treated with protease inhibitors.
    Schmidt HH; Behrens G; Genschel J; Stoll M; Dejam A; Haas R; Manns MP; Schmidt RE
    Antivir Ther; 1999; 4(3):163-70. PubMed ID: 12731756
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adipocyte-derived hormone levels in HIV lipodystrophy.
    Kosmiski L; Kuritzkes D; Lichtenstein K; Eckel R
    Antivir Ther; 2003 Feb; 8(1):9-15. PubMed ID: 12713059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J; Korsheninnikova E; Funahashi T; Matsuzawa Y; Nyman T; Yki-Järvinen H
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1907-10. PubMed ID: 12679491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices.
    Tong Q; Sankalé JL; Hadigan CM; Tan G; Rosenberg ES; Kanki PJ; Grinspoon SK; Hotamisligil GS
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1559-64. PubMed ID: 12679439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens.
    Woerle HJ; Mariuz PR; Meyer C; Reichman RC; Popa EM; Dostou JM; Welle SL; Gerich JE
    Diabetes; 2003 Apr; 52(4):918-25. PubMed ID: 12663461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.
    Badiou S; De Boever CM; Dupuy AM; Baillat V; Cristol JP; Reynes J
    AIDS; 2003 Mar; 17(5):772-4. PubMed ID: 12646808
    [No Abstract]   [Full Text] [Related]  

  • 53. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy.
    Addy CL; Gavrila A; Tsiodras S; Brodovicz K; Karchmer AW; Mantzoros CS
    J Clin Endocrinol Metab; 2003 Feb; 88(2):627-36. PubMed ID: 12574192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
    Sanne I; Piliero P; Squires K; Thiry A; Schnittman S;
    J Acquir Immune Defic Syndr; 2003 Jan; 32(1):18-29. PubMed ID: 12514410
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    Circulation; 2002 Dec; 106(25):3143-421. PubMed ID: 12485966
    [No Abstract]   [Full Text] [Related]  

  • 56. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution.
    Mynarcik DC; Combs T; McNurlan MA; Scherer PE; Komaroff E; Gelato MC
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):514-20. PubMed ID: 12473840
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.
    Young B; Fischl MA; Wilson HM; Finn TS; Jensen EH; DiNubile MJ; Zeldin RK
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):478-82. PubMed ID: 12473835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.
    Schambelan M; Benson CA; Carr A; Currier JS; Dubé MP; Gerber JG; Grinspoon SK; Grunfeld C; Kotler DP; Mulligan K; Powderly WG; Saag MS;
    J Acquir Immune Defic Syndr; 2002 Nov; 31(3):257-75. PubMed ID: 12439201
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia.
    Miller J; Brown D; Amin J; Kent-Hughes J; Law M; Kaldor J; Cooper DA; Carr A
    AIDS; 2002 Nov; 16(16):2195-200. PubMed ID: 12409741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.
    Fichtenbaum CJ; Gerber JG
    Clin Pharmacokinet; 2002; 41(14):1195-211. PubMed ID: 12405866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.